Genmab A/S/€GMAB

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Genmab A/S

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics for the treatment of cancer. The company's core products include a range of proprietary technologies and therapeutic antibodies, most notably DARZALEX (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to advance its research and expand its product offerings. Founded in 1999, the company leverages its proprietary antibody technologies, including the DuoBody and HexaBody platforms, to create differentiated therapies. Its strategic partnerships and emphasis on cutting-edge research provide it with a notable position in the biopharmaceutical industry.

Ticker

€GMAB
Sector

Primary listing

XGAT

Employees

2,639

Headquarters

Copenhagen, Denmark

Genmab A/S Metrics

BasicAdvanced
€17B
15.11
€18.62
0.80
-

Bulls say / Bears say

Genmab is under legal pressure from AbbVie over alleged trade secret theft involving its ADC linker technology. This lawsuit led to a 3.8% drop in Genmab’s U.S. shares and may result in large damages or court injunctions, putting additional strain on the Rina-S pipeline and research costs (Reuters).
Investors reacted unfavorably to Genmab’s $8 billion buyout of Merus, as evidenced by a 4.1% decline in Genmab’s U.S.-listed shares on the day the deal was announced, reflecting doubts about the acquisition's value and concerns over Genmab's ability to successfully integrate the deal (Barron's).
Genmab plans to fund the Merus deal with around $5.5 billion in non-convertible debt, greatly increasing its leverage and potentially limiting its financial ability to invest in other pipeline projects (StockTitan).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €GMAB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs